If you are still having problems viewing this message, please click here for additional help.

British Journal of Cancer

Volume 118, Issue 8

In this issue
Also new


Population attributable fractions continue to unmask the power of prevention

Freddie Bray & Isabelle Soerjomataram

British Journal of Cancer 2018 118 :1031 - 1032; March 23, 2018; 10.1038/s41416-018-0062-5


Abstract | Full Text

Germline mutations as potential causes of childhood solid tumours: comments on the Norwegian childhood cancer cohort study

Yaddanapudi Ravindranath & Logan G Spector

British Journal of Cancer 2018 118 :1033 - 1034; March 29, 2018; 10.1038/s41416-018-0059-0


Abstract | Full Text


A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours

Keith Dredge, Todd V. Brennan, Edward Hammond, Jason D. Lickliter, Liwen Lin et al.

British Journal of Cancer 2018 118 :1035 - 1041; March 13, 2018; 10.1038/s41416-018-0006-0


Abstract | Full Text

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial

Michael L. Maitland, Sarina Piha-Paul, Gerald Falchook, Razelle Kurzrock, Ly Nguyen et al.

British Journal of Cancer 2018 118 :1042 - 1050; March 19, 2018; 10.1038/s41416-018-0020-2


Abstract | Full Text

Prospective evaluation of plasma Epstein–Barr virus DNA clearance and fluorodeoxyglucose positron emission scan in assessing early response to chemotherapy in patients with advanced or recurrent nasopharyngeal carcinoma

Brigette Ma, Edwin P Hui, Ann King, Sing F Leung, Michael KM Kam et al.

British Journal of Cancer 2018 118 :1051 - 1055; March 20, 2018; 10.1038/s41416-018-0026-9


Abstract | Full Text

Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer

Andrés J. Muñoz Martín, Israel Ortega, Carme Font, Vanesa Pachón, Victoria Castellón et al.

British Journal of Cancer 2018 118 :1056 - 1061; March 28, 2018; 10.1038/s41416-018-0027-8


Abstract | Full Text

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells

Angelique Bruyer, Ken Maes, Laurie Herviou, Alboukadel Kassambara, Anja Seckinger et al.

British Journal of Cancer 2018 118 :1062 - 1073; March 02, 2018; 10.1038/s41416-018-0025-x


Abstract | Full Text

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation

Elisabeth F. P. Peterse, Bertine Niessen, Ruben D. Addie, Yvonne de Jong, Arjen H. G. Cleven et al.

British Journal of Cancer 2018 118 :1074 - 1083; March 26, 2018; 10.1038/s41416-018-0050-9


Abstract | Full Text

Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy

N. O. Elander, K. Aughton, P. Ghaneh, J. P. Neoptolemos, D. H. Palmer et al.

British Journal of Cancer 2018 118 :1084 - 1088; March 09, 2018; 10.1038/s41416-018-0005-1


Abstract | Full Text

A shift from papillary to reticular fibroblasts enables tumour–stroma interaction and invasion

Marieke Hogervorst, Marion Rietveld, Frank de Gruijl & Abdoelwaheb El Ghalbzouri

British Journal of Cancer 2018 118 :1089 - 1097; March 19, 2018; 10.1038/s41416-018-0024-y


Abstract | Full Text

Optoacoustics delineates murine breast cancer models displaying angiogenesis and vascular mimicry

Isabel Quiros-Gonzalez, Michal R Tomaszewski, Sarah J. Aitken, Laura Ansel-Bollepalli, Leigh-Ann McDuffus et al.

British Journal of Cancer 2018 118 :1098 - 1106; March 26, 2018; 10.1038/s41416-018-0033-x


Abstract | Full Text

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes

Balázs Győrffy, Lőrinc Pongor, Giulia Bottai, Xiaotong Li, Jan Budczies et al.

British Journal of Cancer 2018 118 :1107 - 1114; March 21, 2018; 10.1038/s41416-018-0030-0


Abstract | Full Text

The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes

Rokaya El Ansari, Madeleine L. Craze, Maria Diez-Rodriguez, Christopher C. Nolan, Ian O. Ellis et al.

British Journal of Cancer 2018 118 :1115 - 1122; March 16, 2018; 10.1038/s41416-018-0038-5


Abstract | Full Text

Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study

Suzanne C. Dixon-Suen, Christina M. Nagle, Aaron P. Thrift, Paul D. P. Pharoah, Ailith Ewing et al.

British Journal of Cancer 2018 118 :1123 - 1129; March 20, 2018; 10.1038/s41416-018-0011-3


Abstract | Full Text

The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015

Katrina F. Brown, Harriet Rumgay, Casey Dunlop, Margaret Ryan, Frances Quartly et al.

British Journal of Cancer 2018 118 :1130 - 1141; March 23, 2018; 10.1038/s41416-018-0029-6


Abstract | Full Text

Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes

Chitra Joseph, Olivia Macnamara, Madeleine Craze, Roslin Russell, Elena Provenzano et al.

British Journal of Cancer 2018 118 :1142 - 1151; March 28, 2018; 10.1038/s41416-018-0041-x


Abstract | Full Text


Comment on ‘BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses'

Willi Sauerbrei & Tim Haeussler

British Journal of Cancer 2018 118 :1152 - 1153; March 15, 2018; 10.1038/s41416-018-0023-z


Abstract | Full Text

Reply to ‘Comment on ‘BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses’’

E. S. Papadakis, T. Reeves, N. H. Robson, T. Maishman, G. Packham et al.

British Journal of Cancer 2018 118 :1154 - 1154; March 15, 2018; 10.1038/s41416-018-0032-y


Abstract | Full Text

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature